Bladder Cancer

October 27, 2020

In patients with muscle-invasive bladder cancer, gemcitabine plus once daily radiation showed a low cystectomy rate and high overall survival rate at long-term follow-up.

October 16, 2020

Stephen B. Williams, MD, MS, discusses a recent study evaluating costs of surgical treatments for bladder cancer.

October 13, 2020

Program encompasses patient counseling, anesthetic planning, and early mobilization.

October 12, 2020

Presurgical treatment with the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab showed promise in cisplatin-ineligible patients with high-risk localized bladder cancer.

October 12, 2020

The antibody-drug conjugate was highly active in patients who received a PD-1/PD-L1 inhibitor but were ineligible for cisplatin.

October 09, 2020

The sensitivity rate for the detection of urothelial carcinoma with the UroCAD urine-based liquid biopsy far exceeded the rate with urine cytology.

October 08, 2020

The OASIS trial is examining the capability of the RENOVA iStim implantable tibial neuromodulation system to reduce urinary urgency incontinence episodes.

October 02, 2020

"Currently, there is significant variability in the design, conduct, and analysis of clinical trials for adjuvant treatment of both kidney cancer and bladder cancer. This variability negatively affects our ability to interpret trial results," said Richard Pazdur, MD.

October 01, 2020

Dual immune checkpoint blockade with the PD-1 inhibitor tislelizumab and the PD-L1 inhibitor BGB-A333 showed clinical activity in bladder cancer.

September 30, 2020

The antibody-drug conjugate is used for the second-line treatment of patients with HER2-positive locally advanced or metastatic urothelial carcinoma.